Genflow Biosciences plc (GENF.L) Research
Genflow Biosciences plc is a biotechnology firm dedicated to devising biological treatments aimed at confronting the impacts of aging. Their goal is to slow down or completely stop the aging process and reduce the frequency of age-related illnesses, thereby extending the period of good health (healthspan). Their primary therapeutic asset is GF-1002, an adeno-associated viral vector-based gene therapy delivered through intravenous infusion. The company's pipeline also features GF-3001, a topical application of SIRT6 for skin treatment, and GF-4001, an anti-aging solution developed for veterinary use in non-human animals. Established in 2021, Genflow Biosciences plc is headquartered in London, United Kingdom.
Market snapshot
- Symbol
- GENF.L
- Price
- $2.03
- Day change
- -2.41%
- Market cap
- $11.5M
- P/E ratio
- -6.14x
- 52-week range
- 0.55-3.12
- Sector
- Healthcare
- Industry
- Biotechnology
Recent news
- Genflow to present beagle gene therapy data at longevity summit
Genflow Biosciences Ltd (LSE:GENF, OTCQB:GENFF, FRA:WQ5), the longevity research company, has been invited to present results from its SLAB clinical study...
- Genflow surges 14% as animal health giants circle canine ageing gene therapy
The AIM-listed biotech's SIRT6 programme is attracting a widening group of Tier-1 industry evaluators, sending shares to 2.85p. Genflow Biosciences Ltd...
- HeLIX Exploration boosted by new US Air Force hydrogen venture
HeLIX Exploration PLC (AIM:HEX, OTCQB:HHEXF) shares moved up 5.2%, rising to 42.13p, after it was selected by Renaissance Philanthropy’s Chimaera Fund to...
Peer companies
Open Genflow Biosciences plc (GENF.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.